Find Locations
For hours, walk-ins and appointments.Expected Turnaround Time
4 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Cerebrospinal fluid (CSF), frozen
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
Plastic (CSF) tube
Collection
Collect CSF by lumbar puncture.
Storage Instructions
Transport frozen.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Hemolysis
Test Details
Use
Quantitative measurement of ACE in CSF. Angiotensin Converting Enzyme (ACE) is used in the assessment of neurosarcoidosis. The major sources of ACE are macrophages and epithelial cells. Patients with sarcoidosis display elevated levels of ACE.
Limitations
Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp.
Methodology
Quantitative spectrophotometry
Reference Interval
See table.
Age | Range (U/L) |
|---|---|
0 to 5 y | Not established |
6 to 17 y | 0.0−2.1 |
18 to 50 y | 0.0−2.5 |
>50 y | 0.0−3.1 |
Additional Information
Angiotensin-converting enzyme catalyzes the formation of angiotensin II by cleaving the C-terminal histidylleucine dipeptide from angiotensin I.1
Indications are that ACE is affiliated with an autonomous renin-angiotensin system of the brain that participates in physiologic processes inside the brain.2,3 Also, studies suggest that changes in ACE concentrations in brain tissue, caused by various neurologic disorders, are reflected by alterations in ACE activity in cerebrospinal fluid (CSF).4
Increased ACE concentrations in CSF are associated with neurosarcoidosis,4-7 with affected patients generally having activities approximately two-fold or more higher than those of healthy individuals.4,6,7
Increased CSF ACE has also been implicated in neurologic diseases, such as bacterial and viral meningitis and Behcet disease.4-7
Decreased concentrations have been reported in patients with Alzheimer disease, Parkinson disease, and progressive supranuclear palsy.8,9
Footnotes
1. Soffer RL. Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu Rev Biochem. 1976;45:73-94.183603
2. Printz MP, Ganten D, Unger T, Phillips MI. Mini review: the brain renin angiotensin system. In: Ganten D, Printz MP, Phillips MI, Scholkens BA, eds. The renin-angiotensin system in the brain. Heidelberg: Springer Verlag, 1982:3-52.
3. Phillips MI, Weyhenmeyer J, Felix D, Ganten D, Hoffman WE. Evidence for an endogenous brain renin-angiotensin system. Fed Proc. 1979 Aug;38:2260-2266.222621
4. Schweisfurth H, Schioberg-Schiegnitz S. Assay and biochemical characterization of angiotensin-I-converting enzyme in cerebrospinal fluid. Enzyme. 1984;32(1):12-19.6090116
5. Chan Seem CP, Norfolk G, Spokes EG. CSF angiotensin converting enzyme in neurosarcoidosis. Lancet. 1985 Feb 23;1(8426):456-457.2857830
6. Oksanen V, Fyhrquist F, Somer H, Gronhagen-Riska C. Angiotensin converting enzyme in CSF: a new assay. Neurology. 1985 Aug;35(8):1220-1223.2991815
7. Jones DB, Mitchell D, Horn DB, Edwards CR. Cerebrospinal fluid angiotensin converting enzyme levels in the diagnosis of neurosarcoidosis. Scott Med J. 1991 Oct;36(5):144-145.1664971
8. Zubenko GS, Volicer L, Direnfeld LK, Freeman M, Langlais PJ, Nixon RA. Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. Brain Res. 1985 Mar 4;328(2):215-221.2985183
9. Zubenko GS, Marquis JK, Volicer L, Direnfeld LK, Langlais PJ, Nixon RA. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Biol Psychiatry. 1986 Dec;21(14):1365-1381.3024746
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 123231 | ACE, CSF | 12480-0 | 123232 | ACE, CSF | U/L | 12480-0 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf